Daraxonrasib Approval Gives Pancreatic Cancer a First RAS Pill

A once-daily pill clears the FDA

Pancreatic cancer is one of the hardest cancers to treat, and for years the main second-line option has been more chemotherapy. On August 26, 2026, the US Food and Drug Administration approved daraxonrasib, sold as Rasonque by Revolution Medicines. It is cleared for adults with metastatic pancreatic adenocarcinoma who have already had at least one systemic therapy or who cannot tolerate multiagent regimens.1 The recommended dose is a 300 mg tablet taken once a day until the disease progresses or side effects become unacceptable.1

The American Cancer Society's write-up carries the headline "Daraxonrasib Shows Promise." It first ran in late July as a guide to an experimental drug and later added an editor's note recording the approval.12 That change in framing sums up the story. In about four months, a drug known mostly through a company press release became a prescribable medicine. It also picked up a recommendation in European guidelines and a positive opinion from the European Medicines Agency's drug committee.525

What the trial showed

The approval rests on RASolute 302, an open-label Phase 3 trial. It randomized 500 patients whose metastatic disease had progressed after one prior line of treatment to receive either daraxonrasib or the chemotherapy their physician chose.1 Median overall survival was 13.2 months on daraxonrasib and 6.7 months on chemotherapy, a 60% reduction in the risk of death (hazard ratio 0.40).19 Median progression-free survival rose from 3.6 to 7.2 months.1 Tumors shrank in 31.6% of patients on the drug and 11.2% on chemotherapy.5

The details people will feel most may be in the quality-of-life data. Patients on daraxonrasib went a median of 9.2 months before their cancer pain clearly worsened, compared with 3.8 months on chemotherapy. Overall quality of life held up for 5.7 months versus 2.6.18 At 12 months, 53.3% of patients in the drug arm were alive, against 18.7% on chemotherapy.18 The lead MSK investigator, Eileen O'Reilly, summed it up by saying patients "live better for longer."13

The science explains why oncologists reacted so strongly. RAS mutations drive more than 90% of pancreatic ductal adenocarcinomas, yet for decades no therapy could hit the target well.13 Daraxonrasib gets around the problem by acting as a "molecular glue" rather than binding RAS directly. It first attaches to a helper protein called cyclophilin A, and that pair then locks onto active RAS and shuts down its growth signals.1719 Because it works across many RAS variants, the benefit held whether or not a patient carried a RAS G12 mutation.16 The FDA label does not require a companion diagnostic, and patients with or without an identified RAS mutation are eligible.7

Where the numbers diverge

The coverage agrees on the main result, but some figures differ in ways readers should understand.

Progression-free survival. Some outlets give 7.3 versus 3.5 months, which is the RAS G12 primary-analysis group. Others give 7.2 versus 3.6, which is the full trial population.51 Both are correct, but they describe different patient groups.

Toxicity. The BBC reported that about 44% of daraxonrasib patients had severe side effects, compared with 57.5% on chemotherapy.10 That matches the company's figure for grade 3 or higher treatment-related events (43.6%).21 Counting all-cause grade 3+ adverse events instead gives 61.8% versus 69.6%.29 Either way the drug comes out ahead, but the all-cause gap is smaller. Side effects are common: diarrhea affected 63.1% of patients, acne-like dermatitis 62.4% and mouth sores 55.5%.25 Skin toxicity overall reached 86%.7 One treatment-related death from pneumonitis was recorded.21 In practice, the drug's advantage is less about having fewer side effects and more about manageable ones. Only 1.2% of patients stopped daraxonrasib because of treatment-related effects, against 11.2% on chemotherapy.21

Durability. A later ad hoc analysis put median overall survival at 12.4 months on the drug and 6.7 on chemotherapy, with a hazard ratio of 0.49.29 The company calls this consistent with the primary analysis. Still, the hazard ratio moving from 0.40 to 0.49 hints that the headline benefit may shrink somewhat with longer follow-up. Even so, it would remain far beyond anything previously seen in this setting.

Overstatement. The Conversation described the survival gain as measured "after diagnosis."17 In fact, overall survival in the trial was counted from the start of treatment in previously treated patients.15 The "doubling" claim needs that context. These patients had already progressed, and the gain is about six and a half months at the median.

The fast lane, and the weight loss drugs that opened it

The regulatory story deserves as much attention as the clinical one. Revolution submitted its application on July 22 and had approval just over a month later.9 The FDA says the decision came about 6.5 months before its formal goal date.1 Daraxonrasib reached that speed through several programs at once. It held breakthrough therapy and orphan drug designations, its data were submitted in pieces before the full filing through the Real-Time Oncology Review pilot, and it was part of the Commissioner's National Priority Voucher (CNPV) program.1

The CNPV pathway is where the cancer story and the weight loss story meet. The voucher program, launched in June 2025, promises reviews of one to two months instead of the usual ten.33 Its first high-profile tests were obesity drugs. Novo Nordisk's higher-dose Wegovy HD was approved in 54 days in March 2026. Eli Lilly's oral GLP-1 orforglipron (Foundayo) followed on April 1 in 50 days, the fastest approval of a new molecular entity since 2002.33 Fierce Pharma called the program "controversial" when Foundayo was cleared.39 Analysts had flagged orforglipron as an ideal candidate because it treats a common chronic condition and could be priced competitively. That framing tied the program to the administration's drug-pricing goals.37

In my reading, daraxonrasib is the strongest case yet for the voucher model. Questions about a review that took weeks are easier to set aside when the drug doubles median survival in a cancer where, by the BBC's account, more than half of patients die within three months of diagnosis.10 The obesity approvals showed the FDA could move fast. Daraxonrasib shows the pathway can also deliver unprecedented results for a disease with few options, which is the language the agency's oncology chief used.5 The uncomfortable implication is that a single pathway now covers both a mass-market lifestyle drug and a last-line cancer therapy. That makes the selection criteria a matter of policy, not just a procedural detail.

It is also worth noting what made such a fast review safe enough here. The trial was large and randomized, and its results were published in the New England Journal of Medicine.18 More than 2,000 patients had already received the drug through expanded access before approval.3 The FDA had real-world exposure data, not just trial data, when it decided.

Commercial stakes and what comes next

Wall Street sees a large launch. RBC analysts projected about $28 million in US pancreatic cancer revenue in the third quarter, rising to as much as $148 million in the fourth.3 One analyst argued the data could support premium pricing as the drug expands into other uses.9 Revolution has launched a support program called (ON)Path to help patients with insurance and costs.7 Price has not appeared in the coverage, and it will decide how far that support needs to stretch.

The next steps are already underway. RASolute 303 is testing daraxonrasib in untreated metastatic disease, alone and with gemcitabine plus nab-paclitaxel. RASolute 304 is testing it after surgery in patients whose tumors were removed.5 A Phase 3 trial in non-small cell lung cancer is also running.9 In Europe, the CHMP's positive opinion now goes to the European Commission for a final decision.25 German financial press notes that the review took less than 150 days, against a standard of up to 210.22

The clinicians who ran the trial are careful to say it is not a cure. O'Reilly called it "a sea change" while stressing that the field is "just at the beginning."13 That is the right way to read it. A median of 13 months is still short for patients and families. The bigger shift is that RAS, long considered undruggable, can now be targeted in the clinic. If the first-line and post-surgery trials deliver, chemotherapy's long hold on pancreatic cancer treatment may finally loosen.